Phibro Animal Health Corporation Class A Stock

$36.69

1.04%

Nasdaq, Sep 02, 10:00 pm CET

ISIN

US71742Q1067

Symbol

PAHC

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Phibro Animal Health Corporation Class A Stock price

$36.69

+16.13 78.43% 5Y

Nasdaq, Closing price Tue, Sep 02 2025

-0.39 1.04%

ISIN

US71742Q1067

Symbol

PAHC

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$1.5b

Enterprise Value

$2.1b

Net debt

$657.1m

Cash

$70.4m

Shares outstanding

40.5m

Valuation (TTM | estimate)

P/E

47.0 | 17.7

P/S

1.2 | 1.1

EV/Sales

1.8 | 1.6

EV/FCF

43.7

P/B

5.6

Dividends

DPS

$0.48

Yield 1Y | 5Y

1.3% | 2.6%

Growth 1Y | 5Y

0.0% | 0.0%

Payout 1Y | 3Y

800.0% | 69.2%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$1.2b | $1.3b

EBITDA

$166.4m | $193.6m

EBIT

$124.0m | $136.6m

Net Income

$31.8m | $84.0m

Free Cash Flow

$49.1m

Growth (TTM | estimate)

Revenue

19.1% | 28.1%

EBITDA

67.3% | 74.8%

EBIT

94.0% | 83.2%

Net Income

141.2% | 3,371.9%

Free Cash Flow

21.6%

Financial Health

Equity Ratio

26.1%

Return on Equity

0.9%

ROCE

11.8%

ROIC

7.4%

Debt/Equity

2.7

EPS

$0.8

FCF per Share

$1.2

Short interest

7.6%

Employees

Rev per Employee

$520.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Phibro Animal Health Corporation Class A Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Phibro Animal Health Corporation Class A forecast:

4x Hold

44%

4x Sell

44%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Phibro Animal Health Corporation Class A forecast:

Buy

11%

Hold

44%

Sell

44%

Analyst Estimates with Stock Price Targets

Financial data from Phibro Animal Health Corporation Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1,191 1,191	19% 19% 100%
- Direct Costs	806 806	16% 16% 68%
Gross Profit	384 384	27% 27% 32%
- Selling and Administrative Expenses	260 260	9% 9% 22%
- Research and Development Expense	- -	- -
EBITDA	166 166	67% 67% 14%
- Depreciation and Amortization	42 42	19% 19% 4%
EBIT (Operating Income) EBIT	124 124	94% 94% 10%
Net Profit	32 32	141% 141% 3%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Phibro Animal Health Corporation Class A Stock News

Neutral

Business Wire

●

about 16 hours ago

Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel. The live audio presentation will be available on...

Positive

Seeking Alpha

●

about 23 hours ago

Phibro Animal Health: Zoetis Growth, Valuation Still Attractive

Phibro Animal Health Corporation's Zoetis MFA acquisition has revitalized its overall growth. Animal Health is now around 75% of their total sales, and its integration should be finalized by Q4 2025. Post-integration, PAHC believes Zoetis MFAs will normalize to flat growth. But, Vaccines and Nutritional Specialties should continue growing at double digits. PAHC's Phibro Forward initiative is al...

Neutral

Seeking Alpha

●

6 days ago

Phibro Animal Health Corporation (PAHC) Q4 2025 Earnings Conference Call Transcript

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q4 2025 Earnings Conference August 28, 2025 9:00 AM ET Company Participants Daniel M. Bendheim - Executive VP of Corporate Strategy & Director Glenn C.

More Phibro Animal Health Corporation Class A News

Company Profile

Phibro Animal Health Corp. engages in the manufacture of animal health and mineral nutrition products. It operates through the following business segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops, manufactures, and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment comprises of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment offers production of specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Head office	United States
CEO	Jack Bendheim
Employees	1,940
Founded	1946
Website	www.pahc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now